Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
JAMA. 2017 Oct 3;318(13):1274-1275. doi: 10.1001/jama.2017.11903.
Are inhaled long-acting muscarinic antagonists (LAMA) combined with long-acting β-agonists (LABA) associated with differences in the incidence of chronic obstructive pulmonary disease (COPD) exacerbation and serious adverse events and with differences in quality of life and forced expiratory volume in the first second of expiration (FEV1) vs inhaled LABA plus inhaled corticosteroids therapy for the treatment of stable COPD?
Compared with inhaled LABA combined with corticosteroids, inhaled LAMA combined with LABA may be associated with a lower risk of COPD exacerbation and with greater improvement in FEV1 without differences in the incidence of serious severe adverse events or quality of life.
与长效β-激动剂（LABA）联合使用的吸入性长效毒蕈碱拮抗剂（LAMA）是否会导致慢性阻塞性肺疾病（COPD）恶化的发生率以及严重不良事件的发生率出现差异，同时对生活质量和第一秒用力呼气量（FEV1）产生影响，与吸入性 LABA 加吸入性皮质类固醇治疗稳定期 COPD 相比？
与吸入性 LABA 联合皮质类固醇相比，吸入性 LAMA 联合 LABA 可能与 COPD 恶化风险降低相关，并且 FEV1 改善程度更大，而严重不良事件或生活质量的发生率则没有差异。
